3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Desmoid Tumors
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Oxaliplatin
64
pembrolizumab
48
Fluorouracil
44
Capecitabine
38
Nivolumab
33
Leucovorin
32
Paclitaxel
28
Trastuzumab
19
Docetaxel
18
Cisplatin
18
S 1 (combination)
16
Bevacizumab
15
Ramucirumab
13
Irinotecan
13
Drug Therapy
13
tislelizumab
12
Cyclophosphamide
12
fludarabine
10
Carboplatin
10
Radiotherapy
9
Magnetic Resonance Spectroscopy
9
trastuzumab deruxtecan
8
sintilimab
8
Specimen Handling
8
Biopsy
8
atezolizumab
7
Surgical Procedures, Operative
7
Gemcitabine
7
zolbetuximab
6
durvalumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
1 year
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled